Skip to main content
. Author manuscript; available in PMC: 2012 Mar 3.
Published in final edited form as: Vaccine. 2011 Jan 6;29(11):2131–2139. doi: 10.1016/j.vaccine.2010.12.087

Figure 1.

Figure 1

Systemic humoral and protective anti-OprF immunity following intramuscular immunization with AdC7OprF and Ad5OprF. C57BL/6 mice were immunized with AdC7OprF, Ad5OprF, Ad5Null or AdC7Null at a dose of 1010 pu/mouse. A. Serum anti-OprF IgG antibodies 0, 4, 8 and 12 wk following administration analyzed by ELISA using recombinant OprF as antigen. B. Serum anti-OprF IgG1, IgG2a, IgG2b and IgG3 antibodies 8 wk following administration. Data are shown as mean ± SEM, n=4/group, of one of three representative experiments. The dashed line represents the limit of detection. C. Protection against pulmonary challenge with P. aeruginosa. Eight wk following immunization mice (n=7/group) were challenged with a lethal intratracheal dose of agar-encapsulated P. aeruginosa (106 cfu), and survival was monitored for 12 days. * and ** denote significance of p<0.05 and ** p<0.01, respectively, between AdC7OprF and Ad5OprF.